DBV

DBV技术将参加即将举行的AAAAI/WAO联合国会DBV Technologies（EuroNext：DBV - ISIN：FR0010417345 - NASDAQ股票市场：DBVT

DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the company will participate in the American Academy of Allergy, Asthma, and Immunology and World Allergy Organization （AAAAI/WAO）联合国会，2月28日，3月3日，2025年3月3日，位于加利福尼亚州圣地亚哥。An oral abstract presentation by Dr. David Fleischer, FAAAAI, FACAAI, Professor of Pediatrics at Children's Hospital Colorado, will describe Month 60 (M60), end-of- study efficacy and safety results from PEOPLE (the open-label extension of the 12- month, double-blind placebo-controlled, Phase 3 PEPITES study in peanut allergic children aged 4-11 years).所有参加人员的合格参与者均接受了Viaskin®Peanut补丁长达60个月的治疗。演示文稿中的要点包括：